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Abstract Recent array-based studies have detected a
wealth of copy number variations (CNVs) in patients with
autism spectrum disorders (ASD). Since CNVs also occur
in healthy individuals, their contributions to the patient’s
phenotype remain largely unclear. In a cohort of children
with symptoms of ASD, diagnosis of the index patient
using ADOS-G and ADI-R was performed, and the Social
Responsiveness Scale (SRS) was administered to the index
patients, both parents, and all available siblings. CNVs
were identified using SNP arrays and confirmed by FISH or
array CGH. To evaluate the clinical significance of CNVs,
we analyzed three families with multiple affected children
(multiplex) and six families with a single affected child
(simplex) in which at least one child carried a CNV with a
brain-transcribed gene. CNVs containing genes that partici-
pate in pathways previously implicated in ASD, such as the
phosphoinositol signaling pathway (PIK3CA, GIRDIN),
contactin-based networks of cell communication (CNTN6),
and microcephalin (MCPH1) were found not to co-segregate
with ASD phenotypes. In one family, a loss of CNTN5 co-
segregated with disease. This indicates that most CNVs may
by themselves not be sufficient to cause ASD, but still may
contribute to the phenotype by additive or epistatic inter-
actions with inherited (transmitted) mutations or non-genetic
factors. Our study extends the scope of genome-wide CNV
profiling beyond de novo CNVs in sporadic patients and
may aid in uncovering missing heritability in genome-wide
screening studies of complex psychiatric disorders.
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Introduction
Autism spectrum disorders (ASDs) represent a group of
neurodevelopmental disorders, which involve deficits in
three areas of functioning: reciprocal social interaction,
communication, and stereotyped and restricted behaviors.
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DOI 10.1007/s10048-011-0297-2When deficits are present in all three domains of function-
ing with at least one defect in one area being detected
before completion of 3 years of age, a classification of
autistic disorder (AD) is warranted [1]. ASDs occur either
sporadically or as familial cases, with an estimated
prevalence of one in 150 children [2]. Males are four times
more frequently affected than females [3]. In 15% to 70%
of children with ASD, also mental and developmental
retardation has been diagnosed [4]. Comparisons of
monozygotic and dizygotic twins suggested a heritability
as high as 90% for the narrow phenotype of AD [5–7].
Analyzing autism risk in multiplex families from the
Autism Genetic Resource Exchange (AGRE), Zhao and
co-workers [8] found strong evidence for dominant trans-
mission to male offspring. They hypothesized that two
types of families may exist: (1) low-risk families with
sporadic autism being mainly caused by spontaneous
mutations with high penetrance in males and relatively
poor penetrance in females; and (2) high-risk families in
whichASDprobandsreceiveadominantmutation,mostoften
from females, who carry this mutation but are themselves
unaffected [8]. Using a Bayesian approach in a population-
based sample, Nishiyama and co-workers showed that the
largest proportion of ASD cases can be explained by a model
allowing multiple, concomitantly inherited risk alleles [9].
ASD emerges increasingly as a genetically heteroge-
neous disorder [7]. Searching for specific ASD risk genes
by genetic linkage and association studies identified only
few of such genes and contributed little to explain the
phenotypic variability among ASD patients. Replication of
results proved to be difficult [4, 7, 10–12]. Genome-wide
segmental aneuploidy profiling revealed submicroscopic
structural genome alterations, named copy number varia-
tions (CNVs), being either inherited or emerging de novo in
7% to 27% of ASD patients under investigation [10, 13–17].
In a recent study of the Autism Genetic Resource Exchange
dataset, Itsara and co-workers found a de novo CNV rate in
the order of 2% and concluded that de novo CNVs may
contribute a significant risk for autism [18]. Given that
CNVs frequently occur in the healthy population [19],
discrimination between neutral variants and pathogenic
events becomes an increasingly difficult and challenging
task. Therefore, it is pivotal to study the relationship between
CNV genotype and clinical phenotype(s) both in ASD
patients and in their parents and siblings [20]. Patients with
ASD in addition to co-morbidities (e.g., dysmorphisms,
congenital anomalies) and a family history of intellectual
impairmentnotonlymakeupthemajorityofcasesbutarealso
morelikelytocarryCNVs[4, 16].Basedonstudies ofCNVs,
a model of ASD etiology, assuming a single or several loci
withadditionaleffects,has beenproposed[21]. In this model,
a CNV by itself may be sufficient to cause ASD or may
contribute additional effect(s) to other mutation(s) such
that via an additive or a synergistic interaction the
threshold for full-blown ASD will be crossed [21, 22].
In order to evaluate the clinical significance of inherited
and de novo CNVs, we followed an unbiased approach by
focusing on patients with co-morbidities in addition to
ASD. These make up the majority of patients seen at our
outpatient department for preschoolers. We selected a
cohort of families in which the index patient carried a
CNV containing at least one gene that is transcribed in the
primary target organ of ASD (i.e., the brain) from the 210
ASD patients referred to our institution at preschool age. In
those families, in which such a CNV was found in the
referred patient, and which had multiple affected children
(multiplex families), all patients, their parents, and all
available siblings were subsequently genotyped by SNP
arrays and were evaluated for behavioral phenotypes using
the Social Responsiveness Scale (SRS) [23–27]. We
assumed that SRS scores above the normal range in any
family member may reflect sub-clinical behavioral impair-
ments. If at least one of the parents scored above the normal
range on the SRS, we assumed that at least one allele
involved in ASD could conceivably have been transmitted
to one or several children with ASD. Thus, following the
Cook and Scherer model [21], CNVs are hypothesized as
being a primary (i.e., sufficient) cause for the ASD phenotype
of the proband when they were inherited from a parent with a
SRS score above the normal range, whereas the other parent
scoredwithinthenormalrange.IncasetheCNVarosede novo
in families in which both parents scored within the normal
range on the SRS, such a CNV was also assumed to be a
primary cause of ASD. In all other cases, a CNV is
hypothesized to be of secondary (i.e., possibly additional)
contribution within a background of other putative suscep-
tibility alleles. Subsequently, we used the same approach to
determine the phenotypic impact of CNVs in families with a
single affected child. Finally, we discuss these outcomes in
terms of the inherited and sporadic forms of ASD [8, 9].
Patients and methods
Ethics statement
Awritten informed consent was obtained from all parents of
the children included in the study. The Medical Ethics
Review Board of the UMC Utrecht approved all procedures.
Psychiatric and clinical genetic evaluation
and patient selection
The 210 children, being consecutively referred with
symptoms of ASD as detected at or before the age of
4 years, have been routinely evaluated by a specialized
316 Neurogenetics (2011) 12:315–323team of clinicians for both their psychiatric and clinical
genetic phenotypes. At this age, a best estimate diagnosis of
ASD was obtained by combining a clinical diagnosis of
ASD (including DSM IV-TR criteria [1]) with an ASD
classification based on a clinical evaluation including the
AutismDiagnosticObservationSchedule-Generic(ADOS-G)
[28], but not the Autism Diagnostic Interview—Revised
(ADI-R) [29]. At the time of the initial evaluation, it was
specified that most of the prototypical autistic behavior is
seen at the ages 4–5 years, and that the ADI-R may be less
specific or sensitive at younger ages [29]. At this initial
evaluation, a psychometric test, the Mullen Scales of Early
Learning (MSEL) [30], was administered to the proband by
a licensed psychologist. The MSEL was used to calculate an
overall cognitive score (CS) (Table 1). If other cognitive tests
are administered at a later age, these later cognitive data are
displayed instead of the data at the initial evaluation (Table 1,
column 3). From our initial cohort, 51 patients did not reach
a best estimate diagnosis and were excluded from this study.
In addition, nine children having a genetic disorder
involving ASD, i.e., Angelman syndrome (OMIM:105830),
neurofibromatosis 1 (OMIM:162200), tuberous sclerosis
(OMIM:191100), Rett syndrome (OMIM:312750), Smith
Lemli Opitz syndrome (OMIM:270400), 22q11.2 deletion
syndrome (VCF) (OMIM:192430), and fragile X syndrome
mental retardation syndrome (OMIM:300624), as well as
children with cytogenetic abnormalities as ascertained by
routine (see below) karyotyping and molecular genetic
diagnosis were also excluded at this step.
Subsequently, probands were investigated according to
standard medical genetic procedures and scored for a
combination of clinical characteristics. Those were family
history of ASD and/or intellectual disability (one point),
intrauterine growth retardation (two points), postnatal
growth disorder (two points), facial dysmorphic features
(two points), minor malformations and congenital anoma-
lies (two points maximum), and neurological disorder (one
point). The cut-off was set at three points in at least two
domains. On the basis of this score, 50 patients were
selected out of the initial cohort of preschoolers with ASD
and were genotyped with SNP arrays (see below). After
detection and evaluation of CNVs as described below, we
retained 13 probands, five from multiplex and eight from
simplex families, who carried a CNV with at least one gene
being transcribed in the brain. These patients were
subsequently evaluated for AD with a standardized inter-
view, the ADI-R [29]. The ADI-R provides a cut-off point;
scores above or on this cut-off point indicate an ADI-R
classification of AD, and a lower score indicates no
classification. If the scoring on the four algorithm items of
the ADI-R reached one point below cut-off, a classification
of ASD was applied. At this stage, one proband did not
reach a best estimate diagnosis of ASD, and three families
(with probands from two multiplex families and one
simplex family) withdrew from this study such that nine
families (with probands from three multiplex and six from
simplex families) participated in the final phase.
In these nine selected families, both parents, the
proband, and siblings were evaluated with the SRS; the
probands and siblings by parent report and the parents by
spouse report. The result of the SRS for parents were
evaluated using the “parent rating raw score means in the
general population”—females: 27.6 (SD 18.1), males: 33.7
(SD 20.9) [24]. Scores of 2 SD above the mean or higher in
parents suggest interference with everyday social interac-
tions and suggest that the parent is affected with features of
a broader phenotype. Scores in parents between 1 SD and
2 SD indicate deficiencies in reciprocal social interaction
and suggest that the parent is partly affected. For children
between 4 and 18 years, the T-score was used [24]. Norms
and validity of the SRS are based on an American population.
Some parents and siblings of our MA families have been
formally diagnosed with ASD according to the criteria of the
DSM-IV-TR, and when available these diagnoses are pre-
sented. All phenotypic data of this final subset of probands
and their parents are summarized in Table 1.
One of the limitations of our study is that when
considering the use of the SRS in an adult population in
research projects, individuals presumed to be substantially
affected on the basis of elevated quantitative traits (SRS)
scores necessitate confirmatory clinical evaluations in large
samples [24, 27]. Acknowledging the fact that autistic
symptoms are continuously distributed in the general
population [23], a boundary between affected and unaffected
is more uncertain [25]. Currently, normative data for adults
are not available. Further studies in adults are needed to
confirm the specificity of the SRS for measuring autistic
social impairment and its relationship to diagnoses of ASD.
Considering children and adolescents (age 4–18 years),
normative SRS data including over 2,500 subjects are
available as yet [23–27], normative data on a Dutch and
Flemish population are pending. In clinical studies, the
specificity of the SRS for measuring autistic social
impairment is highly associated with diagnoses of ASD,
but not with other child psychiatric disorders. The SRS has
been extensively validated in both clinically ascertained and
population-based samples of subjects [23–27].
Karyotyping and molecular genetic analyses
We ascertained all patients’ karyotypes at the 700 band
level in cultured peripheral blood lymphocytes according to
standard procedures. To confirm segmental aneuploidies
detected by the SNP array (see below), BAC-based array
CGH or fluorescence in situ hybridization (FISH) with
region-specific probes was performed [22, 31].
Neurogenetics (2011) 12:315–323 317T
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SNP array
Infinium HumanHap300 Genotyping BeadChip SNP
array analyses were performed according to the protocol
of the manufacturer (Illumina Inc., San Diego, CA,
USA). In a first-pass analysis, CNVs were detected using
the Beadstudio V2.3.41 software package (Illumina Inc.)
as described before (see Supplementary data file S2 in
[32]). Since CNV detection algorithms such as the package
used here detect only part of the CNVs present in the data
[33], all SNP profiles were curated by visual inspection. In
the next step, all CNVs previously detected in the healthy
population were excluded (using the Database of Genomic
Variants; http://projects.tcag.ca/variation). Next, the thus
retained CNVs that contained at least one gene being
transcribed in the clinically relevant target organ [34], i.e.,
the brain—according to the Atlas from the Allen Institute
for Brain Research (http://www.brain-map.org) and the
SESTAN lab (www.humanbrainatlas.org)[ 35], were
retained.
Results
We performed genome-wide CNV profiling of a cohort of
50 probands, 21 from multiplex and 29 from simplex ASD
families (see above). After re-evaluation of the patient’s
phenotype, nine patients (with probands from three multi-
plex and six from simplex families) with a total of two
genomic gains and eight losses were retained (Table 2).
Whereas both gains had arisen de novo, only five out of
eight losses (in four patients) were de novo. Pedigrees of
the three multiplex families with potentially clinically
significant CNVs are displayed in Fig. 1. Only one of the
CNVs, indicated as either a green rim for a gain or a red rim
for a loss, found in our multiplex ASD families appeared to
co-segregate with ASD symptomatology as reflected by
SRS scores of parents and siblings, indicated as numbers
below the symbols (family M2 in Fig. 1 and Tables 1
and 2). For the other multiplex families, it is conceivable
that a mutant allele has been transmitted from a parent
with a SRS score above the normal range. Therefore, the
CNVs may at most exert an additional contribution to the
behavioral phenotype of the patients in these multiplex
ASD families. That means they should be considered
“secondary”. Application of the same SRS-based assess-
ment of segregation of ASD symptomatology to our
simplex families (Fig. 1) shows that only the gain in
3p26 (containing CNTN6 in family S1) and the losses in
7p22.1 and in 12q15 (containing ATXN7,a n dKDELR2,
ZNF12,i nf a m i l yS 2 )m a yb yt h e m s e l v e sb es u f f i c i e n tt o
cause ASD. The de novo gains in 12q15 (containing
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Neurogenetics (2011) 12:315–323 319KCNMB4 in family S3), in 2p16.1 (containing GIRDIN in
family S4), and the de novo losses in 7p31.3 and in 8p23.1
(containing the 5′ part of IMMP2L and the 5′ part of
MCPH1 in Families S5 and S6, respectively) may at most
have exerted an additional effect since transmission of a
dominant mutant allele from a parent with ASD symp-
tomatology (based on SRS scores above the normal range)
can be suspected in each of these families.
In case of a de novo loss, the SNPs from the parental
genome in which the loss occurred will be lost, and
consequently, those from the other parent will be retained.
In one of our cases, the maternal allele was retained while
in another case the paternal allele was found, which is
different from a report on a disruption of CNTNAP2 in a
boy with speech delay and autism spectrum disorder [22].
These findings need further investigation in future studies
of larger cohorts.
Discussion
Copy number variations (CNVs) are the most frequently
detected type of structural genome alterations in ASD
patients [14–17]. In our cohort of multiplex and simplex
families, we found CNVs that contain genes being part of
the phosphoinositol signaling pathway (PIK3CA, GIRDIN)
[17, 36], of the contactin-based networks of cell commu-
nication (CNTN5, CNTN6)[ 36–40], and CNVs encompass-
ing genes such as IMMP2L, MCPH1, and HOXA. Thus, the
CNVs containing at least one brain-transcribed gene
identified candidate genes that are in agreement with
published proposals regarding a pathogenic contribution to
ASD of the phosphoinositol pathway [17, 36], of micro-
cephalin [38, 39], and of the contactin-based networks of
cell communication [40]. The pathways identified in this
study contrast with those found in two studies of patients
with mental retardation and multiple congenital anomalies
[41, 42]. Apparently, our approach to evaluate both de novo
and inherited CNVs in ASD patients allowed us to identify
biological pathways distinct from those involved in mental
retardation and congenital anomalies and likely to be
related to a specific subset of patients with ASD [32].
Yet the contribution of these CNVs to the ASD
phenotype of an individual patient is not a priori clear
[20]. It is frequently assumed that only de novo CNVs
occurring concomitantly with ASD in sporadic patients bear
a causal relationship with the ASD phenotype [14–17].
Since a significant proportion of ASD patients may have
inherited ASD risk, in particular from their healthy mothers
[8, 9], such inherited, yet clinically significant, mutations
and CNVs may thus inadvertently get excluded. Therefore,
it is pivotal to ascertain whether parents, although not being
diagnosed with an outright ASD, may still show some
aspects of ASD symptomatology. For ASD, an increased
rate of less severe, but similar impairments, termed the
broader autism phenotype, is found in 12.4% of the siblings
and in 10–45% of parents of children with ASD [5–7].
Therefore, it is conceivable that in such families the
ASD of the patient may have resulted from interaction
of a de novo or inherited CNV with an inherited allele
from an impaired parent.
To evaluate the potential phenotypic contribution of the
thus identified CNVs, we determined whether a CNV co-
segregated with ASD symptomatology in the family as
reflected by the SRS score of all available family members
in multiplex ASD families. We reasoned that a CNV may
by itself be sufficient to cause the ASD phenotype if it was
either inherited from a parent carrying the same CNV and
showing a SRS score higher than 1 SD above the mean or if
it arose de novo in a single affected child concomitantly
with SRS scores within the normal range (i.e., below 1 SD
Fig. 1 Pedigrees of multiplex and simplex families in which at least
one ASD patient carried CNVs with at least one brain-transcribed
gene. M1 through M3 represent families with multiple affected
children (multiplex); S1 through S6 represent families with a single
affected child (simplex). Filled dark symbols indicate a diagnosis of
autistic disorder; gray symbols autism spectrum disorder; clear
symbols subjects not diagnosed with ASD. Numbers under symbols
indicate the following SRS scores: 0 = 0 SD within normal range,
1 = 1 SD above the mean, and 2 = 2 SD above the mean (for
further explanation, see “Patients and methods” and “Results”
sections). Colored rims indicate CNVs: a green rim represents a
gain; a red rim a hemizygous loss (see also Table 1). The gene names
next to the family numbers indicate the brain-transcribed genes in
the CNVs (same color code as above). The asterisks denote the
index patient of each family
320 Neurogenetics (2011) 12:315–323above the mean) in both parents. Such CNVs, which may
by themselves be “sufficient” to cause ASD symptom-
atology, fit into the leftmost column of the Cook and
Scherer model [21]. In contrast, in families with multiple
affected children, a CNV that arose de novo or did not co-
segregate with SRS-ascertained ASD symptomatology, this
particular CNV may interact with a putative inherited allele.
In these cases, the CNV may exert an additional or epistatic
effect (as represented by columns 2–4 in the Cook and
Scherer model) [21, 22].
According to our SRS-aided segregation analysis in
multiplex families, hemizygosity for PIK3CA and
KCNMB3 (in family M1) or CHL1 and part of CNTN6 (in
family M3) may by itself not be sufficient to cause ASD
(Fig. 1, Tables 1 and 2). Rather, copy number variation of
these genes may act in concert with an, as yet not identified,
inherited mutation located elsewhere in the genome. In
simplex families, however, a gain of part of CNTN6 (in
family S1) or hemizygosity for ATXN7 together with
KDELR3 or ZNF12 (in family S2) may be sufficient to
cause ASD in the affected proband. On the other hand, the
de novo loss of KCNMB4 together with 18 other genes (in
family S3), a gain encompassing GIRDIN (in family S4)
may not be sufficient to cause ASD in the patient since in
both families the mother showed an elevated SRS score
(Fig. 1, Tables 1 and 2). Interestingly, a loss of CHL1 and
part of CNTN6 (in family M3) may exert a weaker
phenotypic effect than the gain of part of the same gene
(in family S1). This is similar to reported findings on the
MCPH1 gene and may indicate a dominant negative effect
of a gain of part of CNTN6 or MCPH1 [40]. This is
analogous to the effects of causal and modifying alleles of
TTC21B in ciliopathies [43].
Only in one of the multiplex families studied a CNV co-
segregating with ASD symptomatology was found. In
contrast, CNVs were found in the other two multiplex
families in which on the basis of the SRS scores of the
parents the existence of an inherited and transmitted
mutation located elsewhere in the genome can be presumed
(Fig. 1a). Similarly, a de novo gain of CNTN6 or a
paternally transmitted loss of CNTN5 (in family M2) may
by itself be sufficient to cause ASD (in family S1), while a
loss of CHL1 and part of CNTN6 (in family M3) may have
to act in concert with a transmitted, presumably mutated,
gene elsewhere in the genome. These findings emphasize
that the phenotypic impact of CNVs of previously published
candidate genes for ASD need to be re-assessed [14–16, 32,
36]. Our data also add to the mounting evidence that two or
even more loci may by additive or epistatic interactions be
involved in the causation of ASD [8, 9, 16, 22].
Systematic evaluation of CNVs, by taking into account
data on gene content and brain transcription, their mode of
inheritance, and the outcome of the SRS in probands and
parents, allowed us to attribute a sufficient or an additional
impact of each CNVon the ASD phenotype of the proband.
Thus, our approach extends the scope of genome-wide
CNV profiling beyond de novo CNVs in sporadic patients.
This also may constitute a first step toward uncovering the
missing heritability in genome-wide screening studies of
complex disorders [44]. Considering the relatively small
size of our sample and that it refers to a specific subset of
patients with ASD, our study does not yet allow for
exhaustiveconclusions[21, 36]. Yet, our study does suggest
that in particular in multiplex ASD families not yet
discovered, dominantly acting mutations or non-genetic
factors may be involved. It is conceivable that in such
families several loci may, by additive of epistatic inter-
actions, provoke the ASD phenotype in some, but not all,
probands. Multiplex families, such as family M1 and M3 in
this study, may represent excellent targets for the novel,
genome-wide next generation sequencing approaches [45].
Future replication of our systematic, family-based approach
to CNV evaluation, complemented by genome-wide re-
sequencing efforts and followed by gene prioritization, may
enhance our insights into the impact of rare genetic variants
on the etiology of ASD and other complex psychiatric
disorders with a high heritability, such as schizophrenia,
and idiopathic mental retardation [46, 47].
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